Related Experiment Videos
Differential expression of folate receptor in pituitary adenomas
Chheng-Orn Evans1, Prasad Reddy, Daniel J Brat
1Department of Neurosurgery, Division of Cancer Biology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Abstract:
Pituitary adenomas cause significant morbidity caused by compression of regional structures or the inappropriate expression of pituitary hormones. However, little is known about the molecular changes that contribute to the development of these tumors. To investigate these changes, we recently used cDNA microarray analysis to identify several genes with altered expression patterns in pituitary adenomas. The folate receptor (FRalpha) was significantly overexpressed in clinically nonfunctional (NF) adenomas but not in functional adenomas (adrenocorticorticotropic hormone, growth hormone, and prolactin). FRalpha is a high affinity folate transporter that is overexpressed by other tumors and could provide a growth advantage to cells that express it. Analysis of FRalpha expression by Western blotting confirmed that FRalpha protein was specifically overexpressed in NF tumors. The FRalpha was capable of binding folates from measurements of [(3)H] folic acid binding, indicating that the overexpressed receptor was properly folded and may mediate vitamin uptake. Comparison of protein and specific [(3)H] folic acid binding levels in subtypes of NF adenomas suggested that the immunohistochemically negative adenomas produced more properly folded FRalpha than adenomas that stained positively for anterior pituitary hormones. Finally, immunohistochemistry demonstrated that FRalpha was specifically expressed in NF adenoma cells. These results demonstrate that overexpression of FRalpha mRNA by NF pituitary adenomas results in production of properly folded FRalpha protein, may mediate vitamin transport, and could potentially facilitate the growth of these tumors.
Insights
Folate receptor alpha (FRalpha) is overexpressed in nonfunctional pituitary adenomas, potentially aiding tumor growth. This study confirms FRalpha protein production and folate binding in these tumors.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Pituitary adenomas cause significant morbidity through compression or hormone overproduction.
- The molecular drivers of pituitary adenoma development remain largely unknown.
- Identifying novel molecular targets is crucial for understanding tumor pathogenesis.
Purpose of the Study:
- To investigate molecular changes in pituitary adenomas.
- To determine the role of folate receptor alpha (FRalpha) in tumor development.
- To assess FRalpha expression and function in different pituitary adenoma subtypes.
Main Methods:
- cDNA microarray analysis to identify differentially expressed genes.
- Western blotting to confirm protein expression levels.
- Radioisotope binding assays to assess folate binding capacity.
- Immunohistochemistry to localize FRalpha expression within tumor tissues.
Main Results:
- FRalpha mRNA was significantly overexpressed in nonfunctional (NF) pituitary adenomas, but not in functional adenomas.
- FRalpha protein was confirmed to be overexpressed in NF tumors.
- Overexpressed FRalpha demonstrated specific folate binding, indicating proper folding and potential vitamin transport.
- Immunohistochemistry revealed FRalpha expression specifically in NF adenoma cells.
Conclusions:
- Overexpression of FRalpha mRNA in NF pituitary adenomas leads to the production of functional FRalpha protein.
- FRalpha may play a role in mediating vitamin transport and facilitating tumor growth.
- FRalpha represents a potential therapeutic target for nonfunctional pituitary adenomas.